According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- the new drug application (“NDA”) for ADX-2191 (a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness;
- as a result, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve the ADX-2191 NDA in its current form;
- accordingly, Aldeyra had overstated ADX-2191’s clinical and/or commercial prospects; and
- as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
